News & Updates

Show Multimedia Only
Dupilumab eases itch, disease activity in chronic spontaneous urticaria
Dupilumab eases itch, disease activity in chronic spontaneous urticaria
16 Jun 2025 byDr. Fernando Martinez, Weil Cornell Medical Center, New York City, New York, US; Dr. Richard Shek-Kwan Chang, Associate Consultant, Division of Neurology, Department of Medicine, Queen Mary Hospital, Hong Kong; รศ. พญ.ชุตินธร ศรีพระประแดง; Dr. Test John Doe, Doctor, Test University of Filipiñas, Ermita, España, Philippines; Dr. Margarita Sánchez del Rio, Clínica Universidad de Navarra, Madrid, Spain; Dr. Christina Man-Tung Cheung, Resident in Dermatology, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong; Stephen Padilla

Patients with chronic spontaneous urticaria (CSA) who has uncontrolled disease despite treatment with H1-antihistamines may benefit from using dupilumab, which has been shown to reduce itch and urticaria activity in two phase III trials.

Dupilumab eases itch, disease activity in chronic spontaneous urticaria
16 Jun 2025